共 14 条
[1]
Chlamydophila pneumoniae ( Chlamydia pneumoniae ) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Ezzahiri R,Nelissen-Vrancken HJ,Kurvers HA,et al. Cardiovascular Research . 2002
[2]
The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. Hu H,Pierce GN,Zhong G. The Journal of Clinical Investigation . 1999
[3]
Chlamydia pneumoniae IgA titres and coronary heart disease: prospective study and meta-analysis. Danesh J,Whincup P,Lewington S,et al. European Heart Journal . 2002
[4]
Evidence for infectious agents in cardiovascular disease and atherosclerosis. Leinonen M,Saikku P. The Lancet Infectious Diseases . 2002
[5]
Libby P,Ridker PM,Maseri A,Inflammation and atherosclerosis. Circulation . 2002
[6]
Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Cercek B,,Shah PK,Noc M, et al. The Lancet . 2003
[7]
The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Epstein SE. Circulation Research . 2002
[8]
Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. Kalayoglu MV,Libby P,Byrne GI. The Journal of The American Medical Association . 2002
[9]
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Center for Disease control (Canada). Dowell SF,Peeling RW,Boman J,et al. Clinical Infectious Diseases . 2001
[10]
Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease:sex-based differences in inflammation and type of immune response. Zhu J,Shearer GM,Norman JE,et al. Circulation . 2000